| Name | Title | Contact Details |
|---|---|---|
Mike Robinson |
VP of Engineering | Profile |
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
Eterna Therapeutics is developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. We and our strategic partners are advancing innovative nucleic acid and cell therapies that offer the hope of radically improving the health outcomes of patients with high unmet medical needs. We are committed to creating a world in which patients and their families have access to effective, life-changing treatments for serious illnesses.
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.
Marlon Ramos at Frange Blue-Hairstylist is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.